Human GM-CSF ELISA Development Kit

Human GM-CSF ELISA development kit is designed for the quantitative measurement within the range of 32-3000 pg/ml of natural or recombinant GM-CSF. Granulocyte-Macrophage Colony Stimulating Factor is a 22 kD, pleiotropic cytokine that is a white blood cell growth factor. It controls the production and function of blood cells by stimulating stem cells to produce granulocytes and monocytes. GM-CSF differs from G-CSF in that it affects more cell types including macrophages and eosinophils. Moreover, GM-CSF is part of the immune/inflammatory cascade, a process crucial for fighting infection. Interestingly, GM-CSF expression may have pathological implications. Autocrine expression of GM-CSF in myeloid leukemia cells is suspected to play a role in neoplasia, the formation of a new and abnormal growth of tissue. Additionally, GM-CSF expression has also been documented in certain solid tumors. There have also been reports of GM-CSF in synovial fluid from patients with arthritis suggesting that GM-CSF may play a role in tissue damage associated with the inflammatory process. Blocking GM-CSF is thought to have therapeutic potential by reducing inflammation. Some drugs are currently being developed to block GM-CSF. Applications include Sandwich ELISA. The term “sandwich” stems from the protein target being bound between two antibodies. The primary antibody is coated to the wells of the microplate. Samples, standards, or controls are then added into these wells, which bind to the immobilized primary antibody. The secondary antibody is added, binding to the primary antibody/target protein complex forming the “sandwich”. Using the provided ELISA protocol, this kit provides sufficient reagents to assay GM-CSF in approximately 1500 ELISA plate wells.